<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To investigate active cytomegalovirus (CMV) <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> following the <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> A (CyA) treatment of steroid-refractory <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> (UC) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Twenty-three patients with severe UC not responding to steroid therapy (male 14, and female 9) enrolled at Nagoya University Hospital from 1999 to 2005 </plain></SENT>
<SENT sid="2" pm="."><plain>They received continuous intravenous infusion of CyA (average 4 mg/kg per day) for 1 mo </plain></SENT>
<SENT sid="3" pm="."><plain>Serum and colonic biopsy samples were collected before CyA treatment and 4 d, 10 d, 20 d, and 30 d after treatment </plain></SENT>
<SENT sid="4" pm="."><plain>Patients were evaluated for CMV by using serology (IgM antibody by ELISA), quantitative real-time PCR for CMV DNA, and histopathological assessment of <z:chebi fb="1" ids="51686">hematoxylin</z:chebi> and eosin (HE)-stained colonic biopsies </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0010823" disease_type="Disease or Syndrome" abbrv="">CMV infection</z:e> was indicated by positive results in any test </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: No patients had active <z:e sem="disease" ids="C0010823" disease_type="Disease or Syndrome" abbrv="">CMV infection</z:e> before CyA treatment </plain></SENT>
<SENT sid="7" pm="."><plain>Eighteen of 23 UC patients treated with CyA were infected with active CMV (IgM antibody in 16/23 patients, 69.6%; CMV DNA in 18/23 patients, 78.2%; and inclusion bodies in 4/23 patients, 17.3%) </plain></SENT>
<SENT sid="8" pm="."><plain>There was no difference in the active <z:e sem="disease" ids="C0010823" disease_type="Disease or Syndrome" abbrv="">CMV-infection</z:e> rate between males and females </plain></SENT>
<SENT sid="9" pm="."><plain>Active <z:e sem="disease" ids="C0010823" disease_type="Disease or Syndrome" abbrv="">CMV infection</z:e> was observed after approximately 8 d of CyA treatment, leading to an exacerbation of <z:hpo ids='HP_0002583'>colitis</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>Fifteen of these 18 patients with active <z:e sem="disease" ids="C0010823" disease_type="Disease or Syndrome" abbrv="">CMV infection</z:e> (83.3%) required surgical treatment because of severe deteriorating <z:hpo ids='HP_0002583'>colitis</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>Treatment with <z:chebi fb="0" ids="465284">ganciclovir</z:chebi> rendered surgery avoidable in three patients </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: Our results suggest that active <z:e sem="disease" ids="C0010823" disease_type="Disease or Syndrome" abbrv="">CMV infection</z:e> in severe UC patients treated with CyA is associated with poor outcome </plain></SENT>
<SENT sid="13" pm="."><plain>Further, <z:chebi fb="0" ids="465284">ganciclovir</z:chebi> is useful for treatment of CMV-associated UC after immuno-suppressive therapy </plain></SENT>
</text></document>